P Vorwerk1, H Wex, B Hohmann, K Mohnike, U Schmidt, U Mittler. 1. Department of Paediatric Oncology, Otto-von-Guericke-University Magdeburg, Emanuel-Larisch-Weg 17-19, D-39112 Magdeburg, Germany. Peter.Vorwerk@medizin.uni-magdeburg.de
Abstract
BACKGROUND: Alterations in the insulin-like growth factor (IGF) system have been reported for different tumours. They are of particular interest in the search for new prognostic and therapeutic approaches in cancer. In childhood acute lymphoblastic leukaemia (ALL) the amount of "tumour mass" at diagnosis can exceed 1 kg. To understand the endocrine, paracrine, and autocrine potential of the malignant transformed progenitor cells, the ability of these cells to express components of the IGF system needs to be investigated. AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL. METHODS: Reverse transcription polymerase chain reaction of Ficoll separated mononuclear cells from 142 children with ALL, 127 cord blood samples, and 55 blood samples of age matched controls were studied. RESULTS: The expression of IGF-I, IGF-II, IGF binding protein 5 (IGFBP-5), and CTGF (IGFBP-rP2) was seen in a higher proportion of mononuclear cells of patients with ALL than in controls. Patients with ALL who were in continuous remission had a lower percentage of IGFBP-2 and IGFBP-3 expressing mononuclear cells at diagnosis than did those who developed a relapse. Only malignant lymphoblasts of B cell origin showed expression of CTGF (IGFBP-rP2). Malignant lymphoblasts of T cell origin more often expressed IGFBP-2 and IGFBP-5, whereas IGF-II and IGFBP-3 expression was seen more often in lymphoblasts of B cell origin. CONCLUSIONS: Malignant lymphoblasts of patients with ALL express components of the IGF system and therefore promote their own growth in an autocrine, paracrine, or endocrine manner. Whether these components will be useful as prognostic factors in the stratification of ALL treatment in children needs to be evaluated.
BACKGROUND: Alterations in the insulin-like growth factor (IGF) system have been reported for different tumours. They are of particular interest in the search for new prognostic and therapeutic approaches in cancer. In childhood acute lymphoblastic leukaemia (ALL) the amount of "tumour mass" at diagnosis can exceed 1 kg. To understand the endocrine, paracrine, and autocrine potential of the malignant transformed progenitor cells, the ability of these cells to express components of the IGF system needs to be investigated. AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL. METHODS: Reverse transcription polymerase chain reaction of Ficoll separated mononuclear cells from 142 children with ALL, 127 cord blood samples, and 55 blood samples of age matched controls were studied. RESULTS: The expression of IGF-I, IGF-II, IGF binding protein 5 (IGFBP-5), and CTGF (IGFBP-rP2) was seen in a higher proportion of mononuclear cells of patients with ALL than in controls. Patients with ALL who were in continuous remission had a lower percentage of IGFBP-2 and IGFBP-3 expressing mononuclear cells at diagnosis than did those who developed a relapse. Only malignant lymphoblasts of B cell origin showed expression of CTGF (IGFBP-rP2). Malignant lymphoblasts of T cell origin more often expressed IGFBP-2 and IGFBP-5, whereas IGF-II and IGFBP-3 expression was seen more often in lymphoblasts of B cell origin. CONCLUSIONS: Malignant lymphoblasts of patients with ALL express components of the IGF system and therefore promote their own growth in an autocrine, paracrine, or endocrine manner. Whether these components will be useful as prognostic factors in the stratification of ALL treatment in children needs to be evaluated.
Authors: H Kanety; Y Madjar; Y Dagan; J Levi; M Z Papa; C Pariente; B Goldwasser; A Karasik Journal: J Clin Endocrinol Metab Date: 1993-07 Impact factor: 5.958
Authors: V Papa; B Gliozzo; G M Clark; W L McGuire; D Moore; Y Fujita-Yamaguchi; R Vigneri; I D Goldfine; V Pezzino Journal: Cancer Res Date: 1993-08-15 Impact factor: 12.701
Authors: Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva Journal: Clin Cancer Res Date: 2015-02-27 Impact factor: 12.531
Authors: Olga Sala-Torra; Holly M Gundacker; Derek L Stirewalt; Paula A Ladne; Era L Pogosova-Agadjanyan; Marilyn L Slovak; Cheryl L Willman; Shelly Heimfeld; David H Boldt; Jerald P Radich Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Catherine Billups; Malcolm A Smith; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2010-12-22 Impact factor: 3.167
Authors: Lihua Ying; Agatha Lau; Cristina M Alvira; Robert West; Gordon M Cann; Bin Zhou; Caroline Kinnear; Eric Jan; Peter Sarnow; Matt Van de Rijn; Marlene Rabinovitch Journal: J Cell Sci Date: 2009-04-14 Impact factor: 5.285